More than 80% of patients with relapsing forms of multiple sclerosis (MS) given Kesimpta (ofatumumab) continuously for up to five years in a clinical trial did not have any documented worsening of…

There was no evidence of multiple sclerosis (MS) disease activity for at least two years in patients who underwent an autologous hematopoietic stem cell transplant (aHSCT) at a center in Mexico. And…

More than 90% of Black and Hispanic patients with multiple sclerosis (MS) treated with Ocrevus (ocrelizumab) in a Phase 4 clinical trial experienced no new relapse activity or sustained disability worsening after…

Treatment with Aubagio (teriflunomide) significantly reduces the risk that adults with radiologically isolated syndrome (RIS) will develop symptoms of multiple sclerosis (MS), new clinical trial data show. This is the second trial…

About 2.5 years of treatment with tolebrutinib was associated with low relapse rates and stable disability levels among people with relapsing forms of multiple sclerosis (MS), according to data in an ongoing,…

Supplements with tauroursodeoxycholic acid (TUDCA) were generally well tolerated among people with progressive forms of multiple sclerosis (MS), according to findings from a small clinical trial. Results also showed that patients given TUDCA…

Use of the cell therapy MSC-NP failed to show a significant effect on overall disability scores among people with progressive forms of multiple sclerosis (MS), according to data from a Phase 2 clinical…

Most treatments for multiple sclerosis (MS) are not associated with an increased risk of complications during pregnancy, according to a new analysis. A few therapies were associated with slightly elevated rates of congenital…